GlassScriptPhysician profile
Rachel Sanger
NPI 1295306405
$6,599.22
in general payments reported to CMS, 2019-2025
45 companies · $985 in 2025
The $985 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,767 · 2022: $1,206 · 2023: $1,885 · 2024: $757 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,626.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $578.72 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $569.92 | 2022-2025 | Lifevest |
| Medtronic, INC. | $556.22 | 2023-2025 | Micra, Aurora Ev-Icd Mri Surescan, Linq II |
| Cvrx, INC. | $470.00 | 2023-2024 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $276.81 | 2023-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $272.97 | 2022-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $268.29 | 2022-2025 | Verquvo |
| Corium, LLC | $256.51 | 2021-2022 | |
| Aquestive Therapeutics, INC. | $247.59 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $209.97 | 2024-2025 | Amvuttra, Onpattro |
| Janssen Pharmaceuticals, INC | $208.05 | 2022-2023 | Xarelto |
| Sunovion Pharmaceuticals INC. | $193.85 | 2021-2022 | |
| Ucb, INC. | $179.91 | 2021-2022 | |
| Pfizer INC. | $168.04 | 2023-2025 | |
| Amgen INC. | $157.03 | 2023-2025 | Repatha, Repatha |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Sanger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.